Your AI-Trained Oncology Knowledge Connection!

Updates in HER2+ Early and Metastatic Breast Cancer : Episode 5

Video

February 7, 2023

Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

Author(s):

Joyce O’Shaughnessy, MD,Virginia Borges, MD

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer

EP: 3.De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

EP: 4.Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

Now Viewing

EP: 5.Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP: 6.Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

EP: 7.Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP: 8.Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

EP: 9.Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

EP: 10.HER2+ mBC: First-Line Treatment Regimens

EP: 11.Second-Line Treatment of HER2+ mBC and Recent Data Updates

EP: 12.Options for Third- and Further-Line Treatment of HER2+ mBC

EP: 13.Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP: 14.Emerging Data and Investigational Agents in HER2+ mBC

EP: 15.Unmet Needs and the Future of HER2+ Breast Cancer Treatment

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity

Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

May 14th 2025 - Jun 19th 2025

online-activity

Latest Conference Coverage

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer

EP: 3.De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

EP: 4.Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

EP: 5.Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP: 6.Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

EP: 7.Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP: 8.Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

EP: 9.Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

EP: 10.HER2+ mBC: First-Line Treatment Regimens

EP: 11.Second-Line Treatment of HER2+ mBC and Recent Data Updates

EP: 12.Options for Third- and Further-Line Treatment of HER2+ mBC

EP: 13.Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP: 14.Emerging Data and Investigational Agents in HER2+ mBC

EP: 15.Unmet Needs and the Future of HER2+ Breast Cancer Treatment

Newsletter

Latest CME

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Indiana

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Indiana

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Indiana

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Latest Conference Coverage